<DOC>
	<DOCNO>NCT01813357</DOCNO>
	<brief_summary>This study randomise double blind placebo control trial comparing Rosuvastatin placbeo HIV positive people intermediate cardiovascular risk . It possible HIV positive people receive great benefit statins high baseline level inflammation . Current Australian guideline recommend initiation statin therapy basis cholesterol level presence risk factor heart disease ( diabetes ) take account whether patient infect HIV . This study aim determine benefit HIV infect people receive start statin therapy earlier currently recommend .</brief_summary>
	<brief_title>Does Rosuvastatin Delay Progression Atherosclerosis HIV</brief_title>
	<detailed_description>Participants randomise receive either active agent ( Rosuvastatin ) placebo daily 96 week . Participants undergo blood test ultrasounds artery neck ( carotid intima medium thickness ) prior start Rosuvastatin 1 2 year drug determine effect marker inflammation , cholesterol level thickness blood vessel .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Age ≥ 18 year Moderate cardiovascular disease ( CVD ) risk , ( 1015 % 10 year risk CVD ) HIV positive Stable combination antiretroviral therapy ( cART ) plasma HIV viral load &lt; 200copies/ml ≥ 6 month Recommended use lipid lowering therapy accord Australian guideline Prior use statin , fibrate , ezetimibe within last six month Contraindication statin use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>HIV</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Statin</keyword>
</DOC>